InDex Pharmaceuticals has carried out a preferential rights issue, which was oversubscribed, of approximately SEK 533 million.
InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine.
Barclays Bank Ireland and Carnegie Investment Bank acted as Joint Global Coordinators and Joint Bookrunners. Baker McKenzie acted as legal advisor to Barclays and Carnegie. Joakim Falkner, Stefan Balazs, Johanna Flink and Ian Gulam from Baker McKenzie's Capital Markets team in Stockholm were involved in the transaction, as well as Adam Farlow, James Thompson, Charles Farnsworth, Paul Andersson and Abigail Saffron from the firm's Capital Markets team in London.